RO7049665

DRUG3 trials

Sponsors

Hoffmann-La Roche

Conditions

Autoimmune Chronic HepatitisAutoimmune HepatitisHealthy VolunteersUlcerative Colitis

Phase 1

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7049665 in Healthy Volunteers

CompletedNCT03221179

Hoffmann-La RocheHealthy Volunteers

Start: 2017-07-10End: 2019-07-05Updated: 2019-08-13

Double-Blinded, Placebo-Controlled Phase 1b Study for Safety, PK, Efficacy, PD of RO7049665 in Participants With Ulcerative Colitis (UC)

TerminatedNCT03943550

Hoffmann-La RocheUlcerative Colitis

Start: 2019-05-13End: 2021-07-22Updated: 2024-02-15

Phase 2

Effect of RO7049665 on the Time to Relapse Following Steroid Tapering in Participants With Autoimmune Hepatitis (AIH)

TerminatedNCT04790916

Hoffmann-La RocheAutoimmune Chronic Hepatitis, Autoimmune Hepatitis

Start: 2021-04-19End: 2021-11-18Updated: 2023-09-18